FMR LLC raised its holdings in shares of Cibus, Inc. (NASDAQ:CBUS - Free Report) by 16.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,913,279 shares of the company's stock after purchasing an additional 566,328 shares during the quarter. FMR LLC owned 14.79% of Cibus worth $12,757,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Armistice Capital LLC bought a new stake in Cibus during the 2nd quarter valued at $5,083,000. Bank of New York Mellon Corp bought a new stake in Cibus during the 2nd quarter valued at $529,000. Old West Investment Management LLC increased its stake in Cibus by 3.6% during the 2nd quarter. Old West Investment Management LLC now owns 53,247 shares of the company's stock valued at $524,000 after purchasing an additional 1,868 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Cibus by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company's stock valued at $161,000 after purchasing an additional 6,276 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in Cibus during the 2nd quarter valued at $221,000. Institutional investors own 33.81% of the company's stock.
Cibus Trading Down 4.6 %
Shares of NASDAQ:CBUS traded down $0.19 during midday trading on Thursday, reaching $3.94. The company had a trading volume of 52,308 shares, compared to its average volume of 134,939. The company's 50 day moving average price is $4.11 and its 200 day moving average price is $6.76. The stock has a market cap of $104.25 million, a P/E ratio of -0.18 and a beta of 1.86. Cibus, Inc. has a 52-week low of $2.86 and a 52-week high of $23.18.
Wall Street Analyst Weigh In
A number of analysts have commented on CBUS shares. HC Wainwright restated a "buy" rating and set a $25.00 price target on shares of Cibus in a research note on Monday, November 11th. Alliance Global Partners cut their price objective on shares of Cibus from $25.00 to $23.50 and set a "buy" rating on the stock in a report on Tuesday, September 24th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $20.00 price objective on shares of Cibus in a report on Tuesday, October 22nd.
Check Out Our Latest Research Report on CBUS
Cibus Profile
(
Free Report)
Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.
Recommended Stories
Before you consider Cibus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cibus wasn't on the list.
While Cibus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
